The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
Open accessAbstract
BACKGROUND: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. METHODS: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. RESULTS: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. CONCLUSIONS: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even among omega‐3 fatty acid studies, there are marked differences with respect to the relatively low doses of omega‐3 administered and the ratio of EPA to DHA.16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ORIGIN trial, which enrolled more than 12,000 patients with impaired fasting glucose and at high risk for cardiovascular events, the administration of 1 g/day of combined EPA + DHA (465 mg of EPA and 375 mg of DHA) had no impact on cardiovascular mortality [89].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, many previous 20 , 21 , 22 , 23 and recently completed clinical studies 24 , 25 showed that ω3 PUFA supplementation did not offer significant favorable impacts on cardiovascular events.”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The STRENGTH, VITAL, ASCEND, ORIGIN, OMEGA, ALPHA-OMEGA, GISSI-HF and GISSI-P trials randomized patients to receive either a combination of EPA and DHA or placebo; yet only the GISSI trials noted a statistically significant effect on cardiovascular events and mortality [96–103].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“but subsequent larger trials failed to replicate these findings. 8,9”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, the dosage used in OMEMI was about twice that used in comparable earlier trials 5, 7, 23, 30 , although considerably lower than the dosage used in REDUCE-IT 14 , and also in the STRENGTH trial 36 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“A limitation to the study is the inclusion rate of 26 % of screened candidates, which is relatively low compared to other n-3 PUFA trials not targeting elderly patients 30-33 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“Other more recent omega‐3 therapy outcome studies conducted in the presence of statins have been less encouraging, but these studies were characterized by evaluating nonhypertriglyceridemic patient populations (eg, TG <200 mg/dL) and administering low doses of long‐chain omega‐3 fatty acids (eg, eicosapentaenoic acid [EPA] and/or docosoahexaenoic acid [DHA]).19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“Our initial manuscript included Trials such as ORIGIN8, ASCEND9, Alpha Omega10, and JELIS5; among these trials, only one trial had IPE, and the rest of the trials had a combination of EPA and DHA, so our results were skewed as search strategy missed significant studies.”
From Cardiovascular outcomes and coronary artery disease prevention secondary to icosapent ethyl: a meta-analysis of randomized clinical trials (2024) · cites this paper as [8]
In the citing paper
“Data from studies on supplementation with n-3 fatty acids do not support recommending n-3 fatty acid supplements for secondary prevention of CVD in T2DM.86,87”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“In the ORIGIN (Outcome Reduction With Initial Glargine Intervention) trial, 12 537 patients (mean age 63.5 years) at high CVD risk with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or T2DM were randomized to insulin glargine titrated to a fasting blood glucose level of ≤5.3 mmol/L (≤95 mg/dL) or standard care.86 After a median follow-up of 6.2 years, the incidence of CV”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“The JELIS study692) conducted in Japan found that the addition of EPA to statins showed a significant preventive effect on major cardiovascular events compared to statin monotherapy.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [692]
In the citing paper
“Evidence does not conclusively support recommending n-3 (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) supplements for all people with diabetes for the prevention or treatment of cardiovascular events (70,209,210).”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [210]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., Franklin, B., Kris-Etherton, P., Harris, W. S., Howard, B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176158 · Cited by 2,705
(1999) · PubMed · Cited by 2,062
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Self-citationGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Fish and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in Women
Hu, F. B. (2002) · JAMA · doi:10.1001/jama.287.14.1815 · Cited by 1,018
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored
Calder, P. C. (2004) · Clinical Science · doi:10.1042/cs20040119 · Cited by 571
Cardiovascular effects of marine omega-3 fatty acids
Saravanan, P., Davidson, N. C., Schmidt, E. B., & Calder, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60445-x · Cited by 513
Flagged first, then by citations
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 201–300 of 933
Harris, W. S., Luo, J., Pottala, J. V., Espeland, M. A., Margolis, K. L., Manson, J. E., Wang, L., Brasky, T. M., & Robinson, J. G. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.12.013 · Cited by 75
Majithia, A., Bhatt, D. L., Friedman, A. N., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.055560 · Cited by 74
Overview of Prescription Omega-3 Fatty Acid Products for Hypertriglyceridemia
WEINTRAUB, H. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2828 · Cited by 74
Wang, T., Zhang, X., Zhou, N., Shen, Y., Li, B., Chen, B. E., & Li, X. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029512 · Cited by 73
Sakamoto, A., Saotome, M., Iguchi, K., & Maekawa, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164025 · Cited by 73
Omega-3 Fatty Acids in Atherosclerosis and Coronary Artery Disease
Bäck, M. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0067 · Cited by 73
Jiao, J., Liu, G., Shin, H. J., Hu, F. B., Rimm, E. B., Rexrode, K. M., Manson, J. E., Zong, G., & Sun, Q. (2019) · BMJ · doi:10.1136/bmj.l4009 · Cited by 71
Brinton, E. A., Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Braeckman, R. A., & Soni, P. N. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-100 · Cited by 70
Brainard, J. S., Jimoh, F. O., Deane, K. H., Biswas, P., Donaldson, D. H., Maas, K., Abdelhamid, A. S., Hooper, L., Ajabnoor, S. M., AlAbdulghafoor, F., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2020.02.022 · Cited by 70
Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia
Gerstein, H. C., Paré, G., McQueen, M. J., Haenel, H., Lee, S. F., Pogue, J., Maggioni, A. P., Yusuf, S., & Hess, S. (2015) · Circulation · doi:10.1161/circulationaha.115.015744 · Cited by 69
Nonstatin Therapies for Management of Dyslipidemia: A Review
Sando, K. R., & Knight, M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.001 · Cited by 69
Chapman, M. J., Zamorano, J. L., & Parhofer, K. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108172 · Cited by 69
The effects of omega-3 polyunsaturated fatty acids on cardiac rhythm: A critical reassessment
Billman, G. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.05.011 · Cited by 69
Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014
Fan, W., Philip, S., Granowitz, C. B., Toth, P. P., & Wong, N. D. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00170-x · Cited by 67
ORIGIN Trial Investigators (2015) · Diabetes Care · doi:10.2337/dc15-1676 · Cited by 66
Djuricic, I. D., & Calder, P. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01363-2 · Cited by 68
Derosa, G., Cicero, A. F. G., D’Angelo, A., Borghi, C., & Maffioli, P. (2016) · BioFactors · doi:10.1002/biof.1277 · Cited by 66
Abnormal Myocardial Dietary Fatty Acid Metabolism and Diabetic Cardiomyopathy
Carpentier, A. C. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.029 · Cited by 66
Liu, Q. K. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.05.007 · Cited by 65
Shen, S., Chen, G., Jin, K., Zhou, L., Xiao, Y., & Ma, L. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.809311 · Cited by 65
Commonly Used Dietary Supplements on Coagulation Function during Surgery
Wang, C., Moss, J., & Yuan, C. (2015) · Medicines · doi:10.3390/medicines2030157 · Cited by 65
Clinical Trial Evidence and Use of Fish Oil Supplements
Grey, A., & Bolland, M. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.12765 · Cited by 64
Maskrey, B. H., Megson, I. L., Rossi, A. G., & Whitfield, P. D. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200723 · Cited by 64
Impact of Genotype on EPA and DHA Status and Responsiveness to Increased Intakes
Minihane, A. M. (2016) · Nutrients · doi:10.3390/nu8030123 · Cited by 64
Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids
Weinberg, R. L., Brook, R. D., Rubenfire, M., & Eagle, K. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.060 · Cited by 63
Xin, W., Wei, W., & Li, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046028 · Cited by 63
Miller, E. R., Juraschek, S. P., Anderson, C. A. M., Güallar, E., Henoch-Ryugo, K., Charleston, J. B., Turban, S., BENNETT, M. R., & Appel, L. J. (2012) · Diabetes Care · doi:10.2337/dc12-1940 · Cited by 63
Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids
Kris‐Etherton, P. M., Richter, C. K., Bowen, K. J., Skulas‐Ray, A. C., Jackson, K. H., Petersen, K. S., & Harris, W. S. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-3-171 · Cited by 63
Alexopoulos, A., Qamar, A., Hutchins, K., Crowley, M. J., Batch, B. C., & Guyton, J. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1136-3 · Cited by 62
Rizos, E. C., Markozannes, G., Τσάπας, Α., Mantzoros, C. S., & Ntzani, E. (2020) · Heart · doi:10.1136/heartjnl-2020-316780 · Cited by 61
The Role of Omega- 3 Polyunsaturated Fatty Acids in Diabetes Mellitus Management: A Narrative Review
Bayram, S. Ş., & Kızıltan, G. (2024) · Current Nutrition Reports · doi:10.1007/s13668-024-00561-9 · Cited by 61
ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity
Luo, M., Liu, A., Wang, S., Wang, T., Hu, D., Wu, S., & Peng, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-02601-7 · Cited by 62
Verma, S., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Dhingra, N. K., Ketchum, S. B., Juliano, R. A., Jiao, L., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.056290 · Cited by 60
Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction
Chiesa, G., Busnelli, M., Manzini, S., & Parolini, C. (2016) · Marine Drugs · doi:10.3390/md14060113 · Cited by 60
Poręba, M., Rostoff, P., Siniarski, A., Mostowik, M., Gołębiowska-Wiatrak, R., Nessler, J., Undas, A., & Gajos, G. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0672-5 · Cited by 60
Dietary and Pharmacological Fatty Acids and Cardiovascular Health
Wu, H., Xu, L., & Ballantyne, C. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz174 · Cited by 59
Fatty acids linked to cardiovascular mortality are associated with risk factors
Ebbesson, S. O. E., Voruganti, V. S., Higgins, P. B., Fabsitz, R. R., Ebbesson, L. O. E., Laston, S., Harris, W. S., Kennish, J. M., Umans, B. D., Wang, H., et al. (2015) · International Journal of Circumpolar Health · doi:10.3402/ijch.v74.28055 · Cited by 60
Abbas, A. M. (2016) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-016-0494-4 · Cited by 59
Toth, P. P., Fazio, S., Wong, N. D., HULL, M. L., & Nichols, G. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13921 · Cited by 59
New Trends in Dyslipidemia Treatment
Jang, A. Y., Lim, S., Jo, S.-H., Han, S. H., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-1037 · Cited by 62
Javaid, M., Kadhim, K., Bawamia, B., Cartlidge, T., Farag, M., & Alkhalil, M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032390 · Cited by 58
The role of marine n-3 fatty acids in improving cardiovascular health: a review
Nicholson, T., Khademi, H., & Moghadasian, M. H. (2013) · Food & Function · doi:10.1039/c2fo30235g · Cited by 58
Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050276 · Cited by 57
Are n-3 fatty acids still cardioprotective?
Harris, W. S. (2012) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32835bf380 · Cited by 57
Omega-3 Fatty Acid Blood Levels Clinical Significance Update
Superko, H. R., Superko, A. R., Lundberg, G. P., Margolis, B., Garrett, B. C., Nasir, K., & Agatston, A. S. (2014) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-014-0407-4 · Cited by 57
Koh, A. S.-M., Pan, A., Wang, R., Odegaard, A., Pereira, M. A., Yuan, J., & Koh, W. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487313517576 · Cited by 57
Rice, H. B., Bernasconi, A. A., Maki, K. C., Harris, W. S., von Schacky, C., & Calder, P. C. (2016) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2016.01.003 · Cited by 57
Lipids and the Endothelium: Bidirectional Interactions
Goldberg, I. J., & Bornfeldt, K. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0365-1 · Cited by 57
The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism
Luo, M., & Peng, D. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0352-y · Cited by 56
The ORIGIN trial investigators, Gilbert, R. E., Mann, J. F. E., Hanefeld, M., Spinas, G. A., Bosch, J., Yusuf, S., & Gerstein, H. C. (2014) · Diabetologia · doi:10.1007/s00125-014-3238-4 · Cited by 55
Self-citationNahab, F. B., Pearson, K. E., Frankel, M., Ard, J. D., Safford, M. M., Kleindorfer, D., Howard, V. J., & Judd, S. E. (2016) · Public Health Nutrition · doi:10.1017/s136898001600152x · Cited by 55
Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids
Handelsman, Y., & Shapiro, M. D. (2016) · Endocrine Practice · doi:10.4158/ep161445.ra · Cited by 55
Are there serious adverse effects of omega-3 polyunsaturated fatty acid supplements?
Lange, K. W., Nakamura, Y., Gosslau, A., & Li, S. (2019) · Journal of Food Bioactives · doi:10.31665/jfb.2019.7192 · Cited by 55
Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects
Pisaniello, A. D., Psaltis, P. J., King, P. M., Liu, G., Gibson, R. A., Tan, J. T. M., Duong, M., Nguyen, T., Bursill, C. A., Worthley, M. I., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.003 · Cited by 55
Casula, M., Olmastroni, E., Gazzotti, M., Galimberti, F., Zambon, A., & Catapano, A. L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105060 · Cited by 54
Harris, W. S., Kennedy, K. F., O’Keefe, J. H., & Spertus, J. A. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.09.076 · Cited by 54
Sekikawa, A. M., Miura, K., Lee, S., Fujiyoshi, A., Edmundowicz, D., Kadowaki, T., Evans, R. G., Kadowaki, S., Sutton-Tyrrell, K., Okamura, T., et al. (2013) · Heart · doi:10.1136/heartjnl-2013-304421 · Cited by 54
Arca, M., Borghi, C., Pontremoli, R., Ferrari, G. M. D., Colivicchi, F., Desideri, G., & Temporelli, P. L. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.001 · Cited by 54
de Lorgeril, M., Salen, P., Defaye, P., & Rabaeus, M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-5 · Cited by 53
Qin, Y., Nyheim, H., Haram, E. M., Moritz, J. M., & Hustvedt, S. O. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0589-0 · Cited by 53
Alfaddagh, A., Elajami, T. K., Saleh, M. A., Mohebali, D., Bistrian, B. R., & Welty, F. K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.04.213 · Cited by 53
Drenjančević, I., & Pitha, J. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042104 · Cited by 52
Zafrir, B., & Jain, M. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6534-9 · Cited by 52
Pitfalls in the use of randomised controlled trials for fish oil studies with cardiac patients
James, M. J., Sullivan, T., Metcalf, R. G., & Cleland, L. G. (2014) · British Journal Of Nutrition · doi:10.1017/s0007114514001408 · Cited by 51
Nutrient reference value: non-communicable disease endpoints—a conference report
Lupton, J. R., Blumberg, J. B., L’Abbé, M. R., LeDoux, M., Rice, H. B., von Schacky, C., Yaktine, A. L., & Griffiths, J. C. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1195-z · Cited by 51
Hermans, M. P., & Valensi, P. E. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000398 · Cited by 51
Darwesh, A. M., Sosnowski, D. K., Lee, T. Y., Keshavarz-Bahaghighat, H., & Seubert, J. M. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.04.037 · Cited by 51
Inflammatory Links Between Hypertriglyceridemia and Atherogenesis
Peng, X., & Wu, H. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01006-w · Cited by 51
Yan, J. R., Liu, M., Yang, D., Zhang, Y., & An, F. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07379-z · Cited by 50
Omega-3 Fatty Acids in Cardiovascular Disease and Diabetes: a Review of Recent Evidence
Bhat, S. Z., Sarkar, S., Zaffar, D., Dandona, P., & Kalyani, R. R. (2023) · Current Cardiology Reports · doi:10.1007/s11886-022-01831-0 · Cited by 51
Dietary fatty acids and lipoprotein metabolism
Ooi, E. M. M., Ng, T. W. K., Watts, G. F., & Barrett, P. H. R. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283613ba2 · Cited by 50
Li, S., Wang, J., Yang, Y., Liu, Z., Cheng, L. Z., Liu, H.-Y., Ma, P., Luo, W. H., & Liu, S. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0834-8 · Cited by 49
A Comparative Overview of Prescription Omega-3 Fatty Acid Products.
Ito, M. K. (2015) · PubMed Central · Cited by 49
Meyer, B. J., & de Groot, R. H. M. (2017) · Nutrients · doi:10.3390/nu9121305 · Cited by 49
Huang, L., Zhang, F., Xu, P., Zhou, Y., Liu, Y., Zhang, H., Tan, X., Ge, X., Xu, Y., Guo, M., et al. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.04.009 · Cited by 48
Bétrisey, S., Haller, M. L., Efthimiou, O., Speierer, A., Giovane, C. D., Moutzouri, E., Blum, M. R., Aujesky, D., Rodondi, N., & Gencer, B. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030714 · Cited by 48
PUFA, genotypes and risk for cardiovascular disease
Panda, C., Varadharaj, S., & Voruganti, V. S. (2021) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2021.102377 · Cited by 48
Wu, J. H. Y., & Mozaffarian, D. (2014) · Heart · doi:10.1136/heartjnl-2013-305257 · Cited by 47
Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022937 · Cited by 47
Self-citationLonn, E., Bosch, J., Díaz, R., López-Jaramillo, P. A., Ramachandran, A., Hâncu, N., Hanefeld, M., Krum, H., Rydén, L., Smith, S. L., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2129 · Cited by 48
Kohashi, K., Nakagomi, A., Saiki, Y., Morisawa, T., Kosugi, M., Kusama, Y., Atarashi, H., & Shimizu, W. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.21022 · Cited by 46
Omega-3 Fatty Acids in Arterial Hypertension: Is There Any Good News?
Brosolo, G., Porto, A. D., Marcante, S., Picci, A., Capilupi, F., Capilupi, P., Bertin, N., Vivarelli, C., Bulfone, L., Vacca, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119520 · Cited by 45
Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia
Pirillo, A., & Catapano, A. L. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.040 · Cited by 45
AlSaleh, A. F. F., Maniou, Z., Lewis, F. J., Hall, W. L., Sanders, T. A. B., & O’Dell, S. D. (2013) · Genes & Nutrition · doi:10.1007/s12263-013-0362-6 · Cited by 45
Zhang, Y.-F., Gao, H.-F., Hou, A., & Zhou, Y. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-204 · Cited by 45
Dietary treatment to lower cholesterol and triglyceride and reduce cardiovascular risk
Welty, F. K. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000689 · Cited by 45
Sekikawa, A., Miyamoto, Y., Miura, K., Nishimura, K., Willcox, B. J., Masaki, K. H., Rodriguez, B., Tracy, R. P., Okamura, T., & Kuller, L. H. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv143 · Cited by 44
Fonollá-Joya, J., Reyes‐García, R., García‐Martin, A., López‐Huertas, E., & Muñoz‐Torres, M. (2016) · Journal of the American College of Nutrition · doi:10.1080/07315724.2014.1003114 · Cited by 44
Nutrition in Type 2 Diabetes and the Metabolic Syndrome
Via, M. A., & Mechanick, J. I. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.06.009 · Cited by 44
Morieri, M. L., Shah, H., Sjaarda, J., Lenzini, P. A., Campbell, H., Motsinger‐Reif, A. A., Gao, H., Lovato, L., Prudente, S., Pandolfi, A., et al. (2020) · Diabetes · doi:10.2337/db19-0973 · Cited by 44
Ooi, E. M. M., Lichtenstein, A. H., Millar, J. S., Diffenderfer, M. R., Lamon‐Fava, S., Rasmussen, H., Welty, F. K., Barrett, P. H. R., & Schaefer, E. J. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p024315 · Cited by 44
Emirates Diabetes Society Consensus Guidelines for the Management of Type 2 Diabetes Mellitus – 2020
Alawadi, F., Abusnana, S., Afandi, B. O., Aldahmani, K. M., Hajeri, O. M. A., Aljaberi, K., Alkaabi, J., Al-Madani, A., Bashier, A. M., Beshyah, S., et al. (2020) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000506508 · Cited by 43
Watanabe, Y., & Tatsuno, I. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1863784 · Cited by 43
Omega-3 and Omega-6 Fatty Acids and Type 2 Diabetes
Jeppesen, C., Schiller, K., & Schulze, M. B. (2013) · Current Diabetes Reports · doi:10.1007/s11892-012-0362-8 · Cited by 43
Li, X., Ballantyne, L. L., Che, X., Mewburn, J. D., Kang, J. X., Barkley, R. M., Murphy, R. C., Yu, Y., & Funk, C. D. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.001856 · Cited by 43
Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?
Serhiyenko, V. A. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i2.245 · Cited by 42
Eide, I. A., Jenssen, T. G., Hartmann, A., Diep, L. M., Dahle, D. O., Reisæter, A. V., Bjerve, K. S., Christensen, J. H., Schmidt, E. B., & Svensson, M. H. S. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11931214 · Cited by 42
The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.001 · Cited by 42
Specialized pro-resolving lipid mediators in cardiovascular disease, diagnosis, and therapy
Kim, A. S., & Conte, M. S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.011 · Cited by 42
Sanders, T. A. B. (2013) · Proceedings of The Nutrition Society · doi:10.1017/s0029665113003789 · Cited by 42
Metadata
- Authors
- The ORIGIN Trial Investigators
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 309-318
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1560062315
- Semantic Scholar
- 00cc8344ced92b3c8921b97df8607e6b3032e111
- Cited by
- 929
- References
- 21
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 41 · 2023: 53 · 2022: 51 · 2021: 57 · 2020: 76 · 2019: 60 · 2018: 72 · 2017: 56 · 2016: 90 · 2015: 79 · 2014: 90 · 2013: 122 · 2012: 38
- FWCI
- 97.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- omega-3 fatty acids, cardiovascular outcomes, type 2 diabetes, dysglycemia, impaired fasting glucose, impaired glucose tolerance, insulin glargine, cardiovascular mortality, major vascular events, triglycerides, serum lipids, cardiac arrhythmias, cardiovascular risk reduction, dietary supplementation, omega-3 fatty acid ethyl esters
- MeSH terms
- Insulin Glargine, Aged, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Treatment Failure, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
